Surgical Adhesives Market by Product (Collagen-Based Adhesives, Cyanoacrylate Adhesives, Fibrin Sealants), Composition (Biological Adhesives, Synthetic Adhesives), Surgical Method, Application, End-User - Global Forecast 2025-2032
Description
The Surgical Adhesives Market was valued at USD 1.75 billion in 2024 and is projected to grow to USD 1.92 billion in 2025, with a CAGR of 9.90%, reaching USD 3.74 billion by 2032.
An incisive introduction that frames the evolving clinical priorities, supply pressures, and innovation imperatives reshaping the surgical adhesives landscape
The surgical adhesives landscape now occupies a central role in perioperative strategy as clinicians, procurement teams, and device innovators converge on alternatives to sutures and staples. Innovations in adhesive chemistry and delivery systems are improving hemostasis, reducing operative time, and supporting minimally invasive approaches, while heightened scrutiny on safety and long-term outcomes is driving more rigorous clinical evaluation. At the same time, supply-chain resilience and cost-efficiency have risen to the top of boardroom agendas, prompting manufacturers to rethink supplier diversification and production footprints.
Consequently, stakeholders must balance clinical efficacy with operational performance and regulatory compliance. Surgeons increasingly select adhesives based on tissue compatibility, handling characteristics, and the evidence base for specific procedures. Meanwhile, hospital and ambulatory administrators weigh device lifecycle costs, training requirements, and inventory complexity. This interplay of clinical preference and institutional constraint defines the strategic context for innovators, setting priorities for incremental improvements in existing chemistries as well as disruptive investments in novel biologics and synthetic platforms. Moving forward, the ability to align product-level differentiation with procurement and clinical pathways will determine competitive positioning.
An authoritative synthesis of the material, procedural, regulatory, and supply-chain transformations that are redefining competitive advantage in surgical adhesives
Over recent years, the surgical adhesives sector has experienced transformative shifts driven by simultaneous advances in biomaterials science and the operational realities of modern healthcare. Developers have pushed beyond traditional cyanoacrylates and fibrin sealants to explore collagen-based and silicone formulations that offer improved biocompatibility and tailored degradation profiles. At the same time, the proliferation of minimally invasive procedures has increased demand for adhesives that perform reliably in constrained working spaces and under endoscopic delivery conditions.
In parallel, regulatory authorities have tightened premarket scrutiny and postmarket surveillance, elevating the importance of robust clinical endpoints and real-world evidence. This regulatory momentum has incentivized strategic partnerships between adhesive manufacturers and clinical research organizations to accelerate evidence generation. Additionally, the supply chain has been reshaped by manufacturers pursuing nearshoring and inventory rationalization to mitigate disruptions. Taken together, these shifts favor companies that combine material science expertise, scalable manufacturing, and deep clinical engagement, while creating opportunities for targeted niche players to capture share in specialized applications through focused clinical validation and surgeon education programs.
A rigorous assessment of how 2025 tariff measures are reshaping sourcing, manufacturing agility, and procurement economics for surgical adhesive manufacturers
Policy shifts affecting tariffs and trade can alter procurement economics and strategic sourcing decisions across the medical device ecosystem, and 2025 has introduced a set of tariff-driven dynamics that require close attention. Manufacturers that historically relied on cross-border sourcing for raw materials, components, or finished adhesives now face an altered cost calculus that may increase landed costs for imports and encourage a reconsideration of supplier footprints. These pressures have prompted some suppliers to assess localized production or to renegotiate supply agreements to preserve margin and delivery reliability.
Beyond cost implications, tariffs influence time-to-market and distribution strategies. Import-sensitive product lines can encounter lead-time uncertainty that compels distributors and hospital purchasers to prioritize stock buffering and supplier redundancy. In addition, tariffs can accelerate vertical integration as manufacturers seek to internalize upstream steps-such as polymer synthesis or sterilization-to reduce exposure to external duties. From a commercial perspective, pricing strategies and contractual terms with large healthcare systems will be adjusted to reflect new cost structures, while regulatory compliance and customs documentation will demand enhanced operational discipline. Overall, the cumulative effect of tariff changes in 2025 is to raise the strategic importance of sourcing flexibility, manufacturing agility, and transparent cost-to-serve analyses across the value chain.
Deep segmentation insights revealing how product types, composition, surgical approach, clinical applications, and care settings uniquely drive development and adoption dynamics
A granular read of segmentation reveals divergent demand drivers and distinct product development priorities across product classes, compositions, surgical methods, applications, and end-user channels. Collagen-based adhesives tend to emphasize biocompatibility and regenerative attributes, making them attractive in orthopedic and cosmetic surgery, whereas cyanoacrylate adhesives are valued for rapid bonding and ease of use in general surgery. Fibrin sealants continue to play a critical role where hemostasis and tissue sealing are paramount, while hydrocolloid and silicone adhesives address wound management and long-term skin compatibility considerations. These product-level differences directly inform formulation roadmaps and clinical trial designs.
Compositionally, biological adhesives prioritize natural substrates and enzymatic compatibility, supporting softer tissue integration, whereas synthetic adhesives focus on tunable mechanical properties and scalable manufacturing. Surgical method segmentation highlights heightened adoption in minimally invasive procedures that demand low-viscosity, endoscopic-deliverable formulations, contrasted with open surgery contexts where handling characteristics and bulk adhesion may dominate selection criteria. Application-wise, cardiovascular surgery imposes stringent sterility and performance requirements; cosmetic surgery emphasizes aesthetics and scar minimization; general surgery values speed and broad applicability; orthopedic surgery seeks load-bearing and long-term stability. Finally, end-user segmentation across ambulatory surgical centers, hospitals & clinics, and specialty care centers shapes purchasing cycles, inventory practices, and training investment, driving differentiated commercial approaches and lifecycle support models.
Key regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine commercialization success for surgical adhesives
Regional dynamics introduce varied regulatory landscapes, clinician preferences, and supply-chain architectures that influence strategy. In the Americas, integrated healthcare systems and consolidated GPO purchasing dynamics accentuate the importance of reimbursement positioning, cost transparency, and strong clinical evidence for adoption. Innovation clusters within North America also accelerate partnership opportunities between adhesive developers and academic centers, supporting early-stage clinical validation and surgeon championing.
Across Europe, Middle East & Africa, regulatory harmonization efforts and national procurement variations require flexible market-entry tactics, with localized clinical data and distribution partnerships often determining success. Reimbursement models in certain European markets reward demonstrated improvements in patient throughput and reduced complications, creating pathways for premium-priced, clinically differentiated adhesives. In the Asia-Pacific region, rapid procedural volume growth and expanding access to advanced surgical care drive demand across both public and private providers, while local manufacturing advantages and cost sensitivity encourage domestic production and licensing collaborations. Transitioning between these regional environments requires manufacturers to adapt regulatory strategies, value messaging, and supply-chain footprints to align with divergent payer expectations and clinical practice patterns.
A strategic appraisal of competitive structures, partnership strategies, and capability gaps that determine which companies will lead in surgical adhesive innovation and commercialization
Competitive dynamics in the surgical adhesives space reflect a blend of incumbent device corporations, specialized adhesive developers, and emergent biotech entrants. Incumbents leverage broad distribution networks and established hospital relationships to scale adoption quickly, yet they must continue to invest in clinical evidence and training programs to defend positions. Specialized developers often compete on formulation novelty and targeted clinical outcomes, pursuing narrow clinical niches or delivery-system integration to differentiate from commodity adhesives. Newer biotech entrants bring advanced biomaterials expertise and may focus on regenerative or tissue-interactive properties that open adjacent indications.
Across this landscape, collaboration patterns matter: strategic partnerships between adhesive innovators and OEMs that supply surgical devices can expedite integrated product offerings, while alliances with contract manufacturers and sterilization providers improve time-to-scale. Intellectual property portfolios and regulatory track records also shape competitive advantage; firms with robust CE and FDA pathways reduce uncertainty for large buyers. Finally, commercial excellence-particularly in surgeon education, real-world outcomes collection, and total cost-of-care demonstrations-remains a decisive factor. Leaders will combine technical innovation with distribution strength and evidence generation to sustain growth and command premium positioning.
Actionable recommendations for R&D, manufacturing, and commercial leaders to strengthen resilience, evidence generation, and adoption pathways in surgical adhesives
Industry leaders must adopt an actionable playbook that aligns R&D investment, manufacturing strategy, and commercial execution with evolving clinical and policy realities. First, prioritize translational research that links material science advances to procedure-specific clinical endpoints; this focus reduces adoption friction by delivering evidence that resonates with surgeon priorities and payer metrics. Next, diversify sourcing and increase manufacturing flexibility to mitigate tariff exposure and supply-chain disruption, including validated dual-sourcing arrangements and selective nearshoring where clinically and economically justified.
Complement these operational moves with disciplined commercial initiatives: invest in structured surgeon training programs, collect robust real-world outcomes data to support reimbursement discussions, and pursue integrated offerings through partnerships with device OEMs. Additionally, tailor regional go-to-market strategies to local regulatory and payer environments, using tiered pricing and localized clinical dossiers where necessary. Finally, embed sustainability and quality assurances into product narratives to meet procurement and hospital sustainability criteria. Together, these steps will position organizations to respond rapidly to policy shifts, capture clinical trust, and sustain differentiated growth in a competitive, evidence-driven landscape.
A clear description of the mixed-methods research approach combining clinical interviews, regulatory documentation, and operational analysis to ensure robust insights and reproducibility
This research synthesizes primary and secondary evidence across clinical, regulatory, and commercial domains using a structured mixed-methods approach. Primary inputs include interviews with clinical leaders across relevant specialties, procurement and supply-chain executives, and senior R&D and regulatory professionals. These interviews were complemented by device labeling and regulatory clearance documentation, peer-reviewed clinical literature, and conference proceedings to triangulate claims around safety, usability, and clinical outcomes. Where possible, real-world use patterns and procedural reports were integrated to validate adoption narratives.
Secondary analysis incorporated manufacturing and distribution workflow assessments, tariff and trade policy reviews, and an audit of public filings and patent landscapes to understand competitive positioning and capability gaps. The methodology emphasizes cross-validation between qualitative stakeholder insights and documented evidence, and it applies scenario-based stress testing to assess the operational impact of tariff and supply-chain variations. Transparency in data sources, conservative interpretation of clinical evidence, and clear delineation of assumptions underpin the analysis, providing decision-makers with a reproducible foundation for strategy development and risk assessment.
A decisive conclusion synthesizing clinical, operational, and commercial imperatives that determine future winners in the surgical adhesives arena
The cumulative analysis demonstrates that surgical adhesives are at an inflection point where material innovation, procedural trends, and policy changes converge to reshape adoption patterns. Clinically, adhesives are moving from adjunctive tools toward integral perioperative technologies when supported by targeted evidence and clinician training. Operationally, supply-chain resilience and manufacturing flexibility are now strategic differentiators, particularly in the context of trade-related cost pressures and heightened procurement scrutiny. Commercially, success will hinge on the ability to connect product performance to measurable clinical and economic outcomes that matter to both surgeons and institutional purchasers.
Looking ahead, organizations that combine differentiated chemistries with scalable production, regulatory readiness, and rigorous outcomes demonstration will be best positioned to lead. Conversely, firms that delay investment in evidence generation or that rely on fragile supply networks risk losing negotiating leverage with large healthcare systems and distributors. In sum, the space rewards integrated strategies that bridge innovation with operational discipline and clinician-centric commercialization models, creating durable value for both patients and health systems.
Note: PDF & Excel + Online Access - 1 Year
An incisive introduction that frames the evolving clinical priorities, supply pressures, and innovation imperatives reshaping the surgical adhesives landscape
The surgical adhesives landscape now occupies a central role in perioperative strategy as clinicians, procurement teams, and device innovators converge on alternatives to sutures and staples. Innovations in adhesive chemistry and delivery systems are improving hemostasis, reducing operative time, and supporting minimally invasive approaches, while heightened scrutiny on safety and long-term outcomes is driving more rigorous clinical evaluation. At the same time, supply-chain resilience and cost-efficiency have risen to the top of boardroom agendas, prompting manufacturers to rethink supplier diversification and production footprints.
Consequently, stakeholders must balance clinical efficacy with operational performance and regulatory compliance. Surgeons increasingly select adhesives based on tissue compatibility, handling characteristics, and the evidence base for specific procedures. Meanwhile, hospital and ambulatory administrators weigh device lifecycle costs, training requirements, and inventory complexity. This interplay of clinical preference and institutional constraint defines the strategic context for innovators, setting priorities for incremental improvements in existing chemistries as well as disruptive investments in novel biologics and synthetic platforms. Moving forward, the ability to align product-level differentiation with procurement and clinical pathways will determine competitive positioning.
An authoritative synthesis of the material, procedural, regulatory, and supply-chain transformations that are redefining competitive advantage in surgical adhesives
Over recent years, the surgical adhesives sector has experienced transformative shifts driven by simultaneous advances in biomaterials science and the operational realities of modern healthcare. Developers have pushed beyond traditional cyanoacrylates and fibrin sealants to explore collagen-based and silicone formulations that offer improved biocompatibility and tailored degradation profiles. At the same time, the proliferation of minimally invasive procedures has increased demand for adhesives that perform reliably in constrained working spaces and under endoscopic delivery conditions.
In parallel, regulatory authorities have tightened premarket scrutiny and postmarket surveillance, elevating the importance of robust clinical endpoints and real-world evidence. This regulatory momentum has incentivized strategic partnerships between adhesive manufacturers and clinical research organizations to accelerate evidence generation. Additionally, the supply chain has been reshaped by manufacturers pursuing nearshoring and inventory rationalization to mitigate disruptions. Taken together, these shifts favor companies that combine material science expertise, scalable manufacturing, and deep clinical engagement, while creating opportunities for targeted niche players to capture share in specialized applications through focused clinical validation and surgeon education programs.
A rigorous assessment of how 2025 tariff measures are reshaping sourcing, manufacturing agility, and procurement economics for surgical adhesive manufacturers
Policy shifts affecting tariffs and trade can alter procurement economics and strategic sourcing decisions across the medical device ecosystem, and 2025 has introduced a set of tariff-driven dynamics that require close attention. Manufacturers that historically relied on cross-border sourcing for raw materials, components, or finished adhesives now face an altered cost calculus that may increase landed costs for imports and encourage a reconsideration of supplier footprints. These pressures have prompted some suppliers to assess localized production or to renegotiate supply agreements to preserve margin and delivery reliability.
Beyond cost implications, tariffs influence time-to-market and distribution strategies. Import-sensitive product lines can encounter lead-time uncertainty that compels distributors and hospital purchasers to prioritize stock buffering and supplier redundancy. In addition, tariffs can accelerate vertical integration as manufacturers seek to internalize upstream steps-such as polymer synthesis or sterilization-to reduce exposure to external duties. From a commercial perspective, pricing strategies and contractual terms with large healthcare systems will be adjusted to reflect new cost structures, while regulatory compliance and customs documentation will demand enhanced operational discipline. Overall, the cumulative effect of tariff changes in 2025 is to raise the strategic importance of sourcing flexibility, manufacturing agility, and transparent cost-to-serve analyses across the value chain.
Deep segmentation insights revealing how product types, composition, surgical approach, clinical applications, and care settings uniquely drive development and adoption dynamics
A granular read of segmentation reveals divergent demand drivers and distinct product development priorities across product classes, compositions, surgical methods, applications, and end-user channels. Collagen-based adhesives tend to emphasize biocompatibility and regenerative attributes, making them attractive in orthopedic and cosmetic surgery, whereas cyanoacrylate adhesives are valued for rapid bonding and ease of use in general surgery. Fibrin sealants continue to play a critical role where hemostasis and tissue sealing are paramount, while hydrocolloid and silicone adhesives address wound management and long-term skin compatibility considerations. These product-level differences directly inform formulation roadmaps and clinical trial designs.
Compositionally, biological adhesives prioritize natural substrates and enzymatic compatibility, supporting softer tissue integration, whereas synthetic adhesives focus on tunable mechanical properties and scalable manufacturing. Surgical method segmentation highlights heightened adoption in minimally invasive procedures that demand low-viscosity, endoscopic-deliverable formulations, contrasted with open surgery contexts where handling characteristics and bulk adhesion may dominate selection criteria. Application-wise, cardiovascular surgery imposes stringent sterility and performance requirements; cosmetic surgery emphasizes aesthetics and scar minimization; general surgery values speed and broad applicability; orthopedic surgery seeks load-bearing and long-term stability. Finally, end-user segmentation across ambulatory surgical centers, hospitals & clinics, and specialty care centers shapes purchasing cycles, inventory practices, and training investment, driving differentiated commercial approaches and lifecycle support models.
Key regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine commercialization success for surgical adhesives
Regional dynamics introduce varied regulatory landscapes, clinician preferences, and supply-chain architectures that influence strategy. In the Americas, integrated healthcare systems and consolidated GPO purchasing dynamics accentuate the importance of reimbursement positioning, cost transparency, and strong clinical evidence for adoption. Innovation clusters within North America also accelerate partnership opportunities between adhesive developers and academic centers, supporting early-stage clinical validation and surgeon championing.
Across Europe, Middle East & Africa, regulatory harmonization efforts and national procurement variations require flexible market-entry tactics, with localized clinical data and distribution partnerships often determining success. Reimbursement models in certain European markets reward demonstrated improvements in patient throughput and reduced complications, creating pathways for premium-priced, clinically differentiated adhesives. In the Asia-Pacific region, rapid procedural volume growth and expanding access to advanced surgical care drive demand across both public and private providers, while local manufacturing advantages and cost sensitivity encourage domestic production and licensing collaborations. Transitioning between these regional environments requires manufacturers to adapt regulatory strategies, value messaging, and supply-chain footprints to align with divergent payer expectations and clinical practice patterns.
A strategic appraisal of competitive structures, partnership strategies, and capability gaps that determine which companies will lead in surgical adhesive innovation and commercialization
Competitive dynamics in the surgical adhesives space reflect a blend of incumbent device corporations, specialized adhesive developers, and emergent biotech entrants. Incumbents leverage broad distribution networks and established hospital relationships to scale adoption quickly, yet they must continue to invest in clinical evidence and training programs to defend positions. Specialized developers often compete on formulation novelty and targeted clinical outcomes, pursuing narrow clinical niches or delivery-system integration to differentiate from commodity adhesives. Newer biotech entrants bring advanced biomaterials expertise and may focus on regenerative or tissue-interactive properties that open adjacent indications.
Across this landscape, collaboration patterns matter: strategic partnerships between adhesive innovators and OEMs that supply surgical devices can expedite integrated product offerings, while alliances with contract manufacturers and sterilization providers improve time-to-scale. Intellectual property portfolios and regulatory track records also shape competitive advantage; firms with robust CE and FDA pathways reduce uncertainty for large buyers. Finally, commercial excellence-particularly in surgeon education, real-world outcomes collection, and total cost-of-care demonstrations-remains a decisive factor. Leaders will combine technical innovation with distribution strength and evidence generation to sustain growth and command premium positioning.
Actionable recommendations for R&D, manufacturing, and commercial leaders to strengthen resilience, evidence generation, and adoption pathways in surgical adhesives
Industry leaders must adopt an actionable playbook that aligns R&D investment, manufacturing strategy, and commercial execution with evolving clinical and policy realities. First, prioritize translational research that links material science advances to procedure-specific clinical endpoints; this focus reduces adoption friction by delivering evidence that resonates with surgeon priorities and payer metrics. Next, diversify sourcing and increase manufacturing flexibility to mitigate tariff exposure and supply-chain disruption, including validated dual-sourcing arrangements and selective nearshoring where clinically and economically justified.
Complement these operational moves with disciplined commercial initiatives: invest in structured surgeon training programs, collect robust real-world outcomes data to support reimbursement discussions, and pursue integrated offerings through partnerships with device OEMs. Additionally, tailor regional go-to-market strategies to local regulatory and payer environments, using tiered pricing and localized clinical dossiers where necessary. Finally, embed sustainability and quality assurances into product narratives to meet procurement and hospital sustainability criteria. Together, these steps will position organizations to respond rapidly to policy shifts, capture clinical trust, and sustain differentiated growth in a competitive, evidence-driven landscape.
A clear description of the mixed-methods research approach combining clinical interviews, regulatory documentation, and operational analysis to ensure robust insights and reproducibility
This research synthesizes primary and secondary evidence across clinical, regulatory, and commercial domains using a structured mixed-methods approach. Primary inputs include interviews with clinical leaders across relevant specialties, procurement and supply-chain executives, and senior R&D and regulatory professionals. These interviews were complemented by device labeling and regulatory clearance documentation, peer-reviewed clinical literature, and conference proceedings to triangulate claims around safety, usability, and clinical outcomes. Where possible, real-world use patterns and procedural reports were integrated to validate adoption narratives.
Secondary analysis incorporated manufacturing and distribution workflow assessments, tariff and trade policy reviews, and an audit of public filings and patent landscapes to understand competitive positioning and capability gaps. The methodology emphasizes cross-validation between qualitative stakeholder insights and documented evidence, and it applies scenario-based stress testing to assess the operational impact of tariff and supply-chain variations. Transparency in data sources, conservative interpretation of clinical evidence, and clear delineation of assumptions underpin the analysis, providing decision-makers with a reproducible foundation for strategy development and risk assessment.
A decisive conclusion synthesizing clinical, operational, and commercial imperatives that determine future winners in the surgical adhesives arena
The cumulative analysis demonstrates that surgical adhesives are at an inflection point where material innovation, procedural trends, and policy changes converge to reshape adoption patterns. Clinically, adhesives are moving from adjunctive tools toward integral perioperative technologies when supported by targeted evidence and clinician training. Operationally, supply-chain resilience and manufacturing flexibility are now strategic differentiators, particularly in the context of trade-related cost pressures and heightened procurement scrutiny. Commercially, success will hinge on the ability to connect product performance to measurable clinical and economic outcomes that matter to both surgeons and institutional purchasers.
Looking ahead, organizations that combine differentiated chemistries with scalable production, regulatory readiness, and rigorous outcomes demonstration will be best positioned to lead. Conversely, firms that delay investment in evidence generation or that rely on fragile supply networks risk losing negotiating leverage with large healthcare systems and distributors. In sum, the space rewards integrated strategies that bridge innovation with operational discipline and clinician-centric commercialization models, creating durable value for both patients and health systems.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
195 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Development of bioresorbable polymer adhesives with controlled degradation rates for patient-specific surgical applications
- 5.2. Integration of antimicrobial and anti-inflammatory agents into surgical adhesives to reduce postoperative infection risk
- 5.3. Advancements in sprayable and aerosolized adhesives for minimally invasive and robotic surgery wound closure
- 5.4. Emergence of hybrid sealant adhesives combining hemostatic and bonding properties for complex cardiovascular procedures
- 5.5. Regulatory approvals accelerating pipeline for polyurethane-based adhesives in orthopedic and tissue engineering markets
- 5.6. Incorporation of nanotechnology and nanoparticles into surgical adhesives to enhance tissue adhesion strength and healing
- 5.7. Development of thermoresponsive adhesives that solidify at body temperature for precision laparoscopic and endoscopic surgeries
- 5.8. Focus on cost-effective single-use delivery systems for surgical adhesives to improve operating room workflow efficiency
- 5.9. Rising adoption of natural and plant-derived adhesives such as fibrin and chitosan for biocompatible wound sealing
- 5.10. Growth of customizable 3D printed adhesive scaffolds for personalized surgical reconstruction and wound management
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Surgical Adhesives Market, by Product
- 8.1. Collagen-Based Adhesives
- 8.2. Cyanoacrylate Adhesives
- 8.3. Fibrin Sealants
- 8.4. Hydrocolloid Adhesives
- 8.5. Silicone Adhesives
- 9. Surgical Adhesives Market, by Composition
- 9.1. Biological Adhesives
- 9.2. Synthetic Adhesives
- 10. Surgical Adhesives Market, by Surgical Method
- 10.1. Minimally Invasive Surgery
- 10.2. Open Surgery
- 11. Surgical Adhesives Market, by Application
- 11.1. Cardiovascular Surgery
- 11.2. Cosmetic Surgery
- 11.3. General Surgery
- 11.4. Orthopedic Surgery
- 12. Surgical Adhesives Market, by End-User
- 12.1. Ambulatory Surgical Centers
- 12.2. Hospitals & Clinics
- 12.3. Specialty Care Centers
- 13. Surgical Adhesives Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Surgical Adhesives Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Surgical Adhesives Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. 3M Company
- 16.3.2. Advanced Medical Solutions Group PLC
- 16.3.3. Artivion, Inc
- 16.3.4. B. Braun Melsungen AG
- 16.3.5. Baxter International Inc.
- 16.3.6. Becton, Dickinson, and Company
- 16.3.7. Cardinal Health, Inc.
- 16.3.8. Chemence Medical, Inc.
- 16.3.9. Connexicon Medical Limited
- 16.3.10. CSL Behring AG
- 16.3.11. GEM S.r.l.
- 16.3.12. GluStitch Inc.
- 16.3.13. Grena Ltd.
- 16.3.14. H.B. Fuller Company
- 16.3.15. Henkel AG & Co. KGaA
- 16.3.16. Integra LifeSciences Holdings Corporation
- 16.3.17. Johnson & Johnson Services, Inc.
- 16.3.18. Kuraray America, Inc.
- 16.3.19. Medline Industries, LP
- 16.3.20. Medtronic PLC
- 16.3.21. Meyer-Haake GmbH Medical Innovations
- 16.3.22. Mitsui Chemicals, Inc.
- 16.3.23. Nordson Corporation
- 16.3.24. Sealantis Ltd.
- 16.3.25. UFP Technologies Inc.
- 16.3.26. Vivostat A/S
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
